Stay updated with breaking news from Interpace Biosciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
●Q3 Revenue of $9.1 million; an 11% increase year-over-year ●Q3 Test volume up 11% year-over-year ●Q3 Reimbursement improvement up 11% year-over-year, driven by additional commercial...
Veracyte's products are marketed as LDTs and are not approved by the FDA. Click here to read more to know the reasons why VCYT stock has a Hold rating.
PARSIPPANY, NJ, Oct. 20, 2022 (GLOBE NEWSWIRE) -- Interpace Biosciences, Inc. (“Interpace” or the “Company”) (OTCQX: IDXG), a fully integrated commercial...
NEW YORK, Sept. 7, 2022 /PRNewswire/ -- According to the latest report published by Growth Plus Reports, the global microRNA market is expected to clock US$ 846.33 million by 2030 and to grow
/PRNewswire/ -- Flagship Biosciences, Inc., a leader in spatial biology and biomarker analytics services, announced the acquisition of Interpace Pharma...